PharmaCyte Biotech Inc (PMCB)

[concordia]

Saying that the trial will be stopped at 6 months is also a misleading statement and the CEO should also address this next week. A trial length is based on total enrollment what the primary endpoint is (is this case progression free survival) and how quickly they can enroll patients. To say a trial is only going to last a year with a 6 month analysis is a "best guess". Anyone who invests in bio tech should know that. Patient participation is declining every year while new clinical trial numbers increase. So far this company has not met one milestone it set for itself and the stock price has suffered badly for it to the point that even good news is met with disbelief by investors. As shareholders we should demand well thought out milestones and hold management accountable to hitting them.